Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.

Adult Female Humans Middle Aged Biomarkers Cross-Sectional Studies Elasticity Imaging Techniques / methods Fibrosis Liver / diagnostic imaging Magnetic Resonance Imaging / methods Non-alcoholic Fatty Liver Disease / diagnostic imaging Prospective Studies

Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
10 2023
Historique:
pmc-release: 01 10 2024
medline: 1 11 2023
pubmed: 10 10 2023
entrez: 10 10 2023
Statut: ppublish

Résumé

Background There is a need for reliable noninvasive methods for diagnosing and monitoring nonalcoholic fatty liver disease (NAFLD). Thus, the multidisciplinary Non-invasive Biomarkers of Metabolic Liver disease (NIMBLE) consortium was formed to identify and advance the regulatory qualification of NAFLD imaging biomarkers. Purpose To determine the different-day same-scanner repeatability coefficient of liver MRI biomarkers in patients with NAFLD at risk for steatohepatitis. Materials and Methods NIMBLE 1.2 is a prospective, observational, single-center short-term cross-sectional study (October 2021 to June 2022) in adults with NAFLD across a spectrum of low, intermediate, and high likelihood of advanced fibrosis as determined according to the fibrosis based on four factors (FIB-4) index. Participants underwent up to seven MRI examinations across two visits less than or equal to 7 days apart. Standardized imaging protocols were implemented with six MRI scanners from three vendors at both 1.5 T and 3 T, with central analysis of the data performed by an independent reading center (University of California, San Diego). Trained analysts, who were blinded to clinical data, measured the MRI proton density fat fraction (PDFF), liver stiffness at MR elastography (MRE), and visceral adipose tissue (VAT) for each participant. Point estimates and CIs were calculated using χ

Identifiants

DOI: 10.1148/radiol.231092 PMID: 37815451 PMC: PMC10625902
pubmed: 37815451
doi: 10.1148/radiol.231092
pmc: PMC10625902
doi:

Substances chimiques

Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT05081427']

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e231092

Subventions

Organisme : NIBIB NIH HHS
ID : R01 EB001981
Pays : United States
Organisme : NIBIB NIH HHS
ID : R37 EB001981
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001442
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Radiology. 2013 Aug;268(2):411-9
pubmed: 23564711
Mayo Clin Proc. 2022 Feb;97(2):225-237
pubmed: 34598789
Clin Gastroenterol Hepatol. 2010 Oct;8(10):877-83
pubmed: 20362695
J Magn Reson Imaging. 2014 Feb;39(2):326-31
pubmed: 23589232
NMR Biomed. 2015 Dec;28(12):1747-53
pubmed: 26768490
Magn Reson Med. 2020 Dec;84(6):3146-3156
pubmed: 32519807
Aliment Pharmacol Ther. 2015 Jun;41(12):1271-80
pubmed: 25873207
J Magn Reson Imaging. 2016 Feb;43(2):398-406
pubmed: 26201284
Sci Rep. 2022 Dec 19;12(1):21925
pubmed: 36535977
Med Phys. 2021 Aug;48(8):4375-4386
pubmed: 34105167
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
J Magn Reson Imaging. 2014 Feb;39(2):440-7
pubmed: 23596052
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Curr Opin Gastroenterol. 2020 May;36(3):184-191
pubmed: 32097176
Radiology. 2017 May;283(2):438-449
pubmed: 28278002
Hepatology. 2018 May;67(5):2001-2012
pubmed: 29059456
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Clin Liver Dis. 2007 Feb;11(1):17-23, vii
pubmed: 17544969
J Magn Reson Imaging. 2011 Oct;34(4):947-55
pubmed: 21751289
Nat Med. 2022 Mar;28(3):430-432
pubmed: 35145308
Hepatology. 2013 Dec;58(6):1930-40
pubmed: 23696515
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Hepatology. 2014 Dec;60(6):1920-8
pubmed: 25103310
Hepatology. 2018 Aug;68(2):763-772
pubmed: 29356032
PLoS One. 2016 Sep 23;11(9):e0163332
pubmed: 27662190
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1974-1982.e7
pubmed: 29104128
Abdom Imaging. 2015 Apr;40(4):810-7
pubmed: 25742725
J Magn Reson Imaging. 2020 Feb;51(2):407-414
pubmed: 31168893
Stat Methods Med Res. 2015 Feb;24(1):27-67
pubmed: 24919831
Hepatology. 2016 Feb;63(2):453-61
pubmed: 26560734
J Magn Reson Imaging. 2010 Mar;31(3):725-31
pubmed: 20187219
J Magn Reson Imaging. 2019 Jul;50(1):305-314
pubmed: 30430684
Radiology. 2017 Oct;285(1):92-100
pubmed: 28530847
Gastroenterology. 2016 Mar;150(3):553-6
pubmed: 26820053

Auteurs

Kathryn J Fowler (KJ)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0001-9188-1701

Sudhakar K Venkatesh (SK)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0002-7514-1030

Nancy Obuchowski (N)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Michael S Middleton (MS)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Jun Chen (J)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0003-0563-542X

Kay Pepin (K)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Jessica Magnuson (J)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0009-0004-9953-1684

Kathy J Brown (KJ)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Danielle Batakis (D)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Walter C Henderson (WC)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0001-8225-4722

Sudha S Shankar (SS)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Tania N Kamphaus (TN)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Alex Pasek (A)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0009-0006-1186-6303

Roberto A Calle (RA)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0001-6577-5657

Arun J Sanyal (AJ)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0001-8682-5748

Rohit Loomba (R)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).

Richard Ehman (R)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0001-7041-5074

Anthony E Samir (AE)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0002-7801-8724

Claude B Sirlin (CB)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0002-6639-9072

Sarah P Sherlock (SP)

From the Liver Imaging Group (K.J.F., M.S.M., D.B., W.C.H., C.B.S.) and Department of Hepatology (R.L.), University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122; Department of Radiology, Mayo Clinic, Rochester, Minn (S.K.V., J.C., K.P., J.M., K.J.B., R.E.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Pfizer Research and Development, Pfizer, Inc, Sacramento, Calif (S.S.S.); Foundation for the National Institutes of Health, North Bethesda, Md (T.N.K., A.P.); Regeneron Pharmaceuticals, Inc, Tarrytown, NY (R.A.C.); Department of Gastroenterology, Virginia Commonwealth University, Richmond, Va (A.J.S.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.E.S.); and Department of Imaging Alliances, Pfizer, Inc, New York, NY (S.P.S.).
ORCID: 0000-0001-5351-3828

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Échographie › Imagerie d'élasticité tissulaire › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Système digestif › Foie › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Stéatose hépatique › Stéatose hépatique non alcoolique › Repeatability of MRI Biomarkers in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Repeatability of MRI Biomarkers in...